Disease Acronyms Flashcards
SMM
Smoldering Multiple Myeloma
NDMM
Newly Diagnosed Multiple Myeloma
TE NDMM
Transplant Eligible Newly Diagnosed Multiple Myeloma
TIE NDMM
Transplant Ineligible Newly Diagnosed Multiple Myeloma
RRMM
Relapsed/Refractory Multiple Myeloma
RR or R/R
Relapsed/Refractory
Relapsed
Responded but stopped responding after 6 months
Refractory
Does not result in remission or gets worse within six months.
Overall Survival (OS)
Duration of patient survival from time of initial treatment.
Progression Free Survival (PFS)
The time from treatment initiation to progression/worsening of the disease
Complete Response (CR)
Absence of all detectable cancer following completion of treatment
Stringent Complete Response (SCr)
In addition to absence of all detectable cancer following completion of treatment, patient has:
1) normal free light chain ratio in serum and
2) absence of clonal cells in the bone marrow
Light Chains
Proteins produced by plasma cells which link to heavy chains to produce immunoglobulins.
Immunoglobulins
Antibodies
Free Light Chains (FLC) or Serum Free Light Chains (SFLC)
Light Chains that are not part of whole immunoglobulins and are present in the blood
Partial Response (PR)
1) At least 50% reduction in serum monoclonal protein ; and
2) At least 90% reduction in 24-hour urine monoclonal protein, up to 200 mg/ 24h
Very Good Partial Response (VGPR)
1) Monoclonal protein levels detectable by immunofixation, but not on electrophoresis, in serum and urine;
2) At least 90% reduction in serum monoclonal protein; and
3) monoclonal protein level in urine <100mg/24h
Overall Response Rate (ORR)
Sum of SCr, CR, PR, and VGPR.
Electrophoresis
Separation of proteins based on physical properties, and using subsets of these proteins to interpret results of multiple myeloma test.
Immunofixation
Tests that determine levels of monoclonal protein
Minimal Residual Disease (MRD)
Presence of a small number of myeloma cells in body after responding well to therapy.
Duration of Response (DOR)
Length of time disease/cancer remains in remission after treatment.
How is Duration of Response (DOR) calculated?
From time of first recorded achievement of particular response level.
Time to Disease Progression (TTP)
Time from randomization until objective tumor progression, excluding death.
Median Follow Up (mFU)
Median time between a specific event and when outcomes data are collected
